WALTHAM, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced today that it has finished its data analysis from a recently completed ALTU-238 Phase 1 study. ALTU-238 is being developed as a subcutaneously administered, long acting formulation of recombinant human growth hormone that employs Altus' proprietary protein crystallization and formulation technology, for patients with growth hormone deficiencies.
